CureMeAbroad Raises $1.1M to Help Patients Find Care Abroad

CureMeAbroad, a platform that helps international patients find, verify and book treatment at hospitals abroad, has raised $1.1 million in a pre-seed round led by healthcare-focused VC firm SteerX Ventures. Existing investor AIRA also joined the round.

The more interesting number here isn’t the $1.1 Mn it’s the gap between where CureMeAbroad stands today and where it says it’s headed. The startup currently runs at a $4.8 million booking rate, but is targeting $100 million in annual patient bookings by FY2028 a roughly 21x jump in under three years.

That’s an aggressive target for a company that’s barely 16 months old, and it tells you this round isn’t about survival. It’s about proving the model fast enough to raise a much bigger round behind it.

The Details

• Round size$1.1 million, Pre-Seed
• Lead investorSteerX Ventures (healthcare-focused VC)
• Also participatingAIRA (existing investor)
• Prior round$600,000 raised in April 2026 from angels including Roman Saini, Himanshu Ratnoo and Kunal Gupta
• Total raised to date$1.7 million across two rounds
• Current run rate$4.8 Mn in annual patient bookings
• Target$100 Mn in annual bookings by FY2028 implying ~21x growth from today

One Platform, Six Countries of Hospitals

Founded in June 2025 by Aditya Oza and Mikhail Bohra, CureMeAbroad lets patients compare hospitals, verify providers, get treatment estimates, and book care all before they ever board a flight.

The platform already has a hospital network spanning six countries, and pulls in over 22,500 monthly visitors. Its core patient base comes from the US, UK, Australia and Canada.

What’s notable is the direction of travel. Most Indian medical tourism platforms are built to bring patients into India. CureMeAbroad instead routes Western patients to multiple destinations India among them, alongside countries like Turkey and Mexico making it less India-specific and more of a global routing layer.

Why $4.8 Mn Isn’t the Same as Revenue

It’s worth being precise about that $4.8 Mn figure it’s a booking run rate, not confirmed revenue. Medical tourism platforms typically earn a commission on bookings, not the full treatment value, so CureMeAbroad’s actual revenue is almost certainly a fraction of that number.

This distinction matters because the $100 Mn FY2028 target is also framed as bookings, not revenue. A platform can hit a huge bookings number while still earning a modest take-rate so the real question for investors isn’t booking volume, it’s margin per booking as the company scales.

The fresh capital will go toward expanding the hospital network, strengthening its AI-powered matching technology, entering new patient markets, and building out operations and tech teams. CureMeAbroad also plans to push into non-elective specialties like orthopaedics and oncology categories with longer decision cycles but potentially higher-value bookings.

A Crowded Field Competing on Trust

CureMeAbroad competes globally with Bookimed, PlacidWay, The Medical Tourism Company and Medical Departures, and in India specifically with Vaidam Health. It’s a space where the real moat isn’t discovery it’s verification and trust, since patients are making high-stakes decisions about surgery in a country they’ve likely never visited.

The company’s Medical Travel Facilitator Certification from Global Healthcare Accreditation is a small but meaningful signal here it’s the kind of third-party trust marker that matters more in healthcare than in most other marketplace categories.

What the Numbers Don’t Tell You

A 21x bookings target in under three years is the kind of number that gets attention and skepticism in equal measure. Medical tourism is a trust-heavy, slow-decision category; patients don’t book surgery abroad the way they book a flight. The real test for CureMeAbroad isn’t traffic growth, it’s conversion from browsing to booked, verified treatment, a metric none of the available reporting actually discloses. Until that number is public, the bookings target is more of a founder ambition than a forecast.

The Bottom Line

CureMeAbroad has the hospital network and the traffic what it hasn’t proven yet is whether browsers actually convert into booked patients at the rate its $100 Mn target assumes.